A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer

John J. Arcaroli, W. M. Tai, Ryan Mcwilliams, Stacey Bagby, Patrick J. Blatchford, Marileila Varella-Garcia, Alicia Purkey, Kevin S. Quackenbush, Eun Kee Song, Todd M. Pitts, Dexiang Gao, Chris Lieu, Martine Mcmanus, Aik-Choon Tan, Xianxian Zheng, Qin Zhang, Mark Ozeck, Peter Olson, Zhi Qin Jiang, Scott KopetzAntonio Jimeno, Stephen Keysar, Gail Eckhardt, Wells A. Messersmith

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Dysregulation of the Notch1 receptor has been shown to facilitate the development and progression of colorectal cancer (CRC) and has been identified as an independent predictor of disease progression and worse survival. Although mutations in the NOTCH1 receptor have not been described in CRC, we have previously discovered a NOTCH1 gene copy number gain in a portion of CRC tumor samples. Here, we demonstrated that a NOTCH1 gene copy number gain is significantly associated with worse survival and a high percentage of gene duplication in a cohort of patients with advanced CRC. In our CRC patient-derived tumor xenograft (PDTX) model, tumors harboring a NOTCH1 gain exhibited significant elevation of the Notch1 receptor, JAG1 ligand and cleaved Notch1 activity. In addition, a significant association was identified between a gain in NOTCH1 gene copy number and sensitivity to a Notch1-targeting antibody. These findings suggest that patients with metastatic CRC that harbor a gain in NOTCH1 gene copy number have worse survival and that targeting this patient population with a Notch1 antibody may yield improved outcomes. What's new? There is mounting evidence that the Notch1 receptor is important in modulating tumor growth and an independent predictor of survival in colorectal cancer (CRC). While mutations in the NOTCH1 receptor have not yet been described in CRC, this study shows that a gain in NOTCH1 gene copy number is associated with worse survival. Targeting cells with a specific Notch1 antibody resulted in potent antitumor growth in a CRC patient-derived tumor xenograft model. A NOTCH1 gene copy number gain may thus be a prognostic marker for disease recurrence as well as a predictive biomarker of sensitivity to a Notch1 targeted therapy.

Original languageEnglish
Pages (from-to)195-205
Number of pages11
JournalInternational Journal of Cancer
Volume138
Issue number1
DOIs
Publication statusPublished - 2016 Jan 1
Externally publishedYes

Fingerprint

Gene Dosage
Colorectal Neoplasms
Biomarkers
Survival
Antibodies
Notch1 Receptor
Heterografts
Neoplasms
Mutation
Gene Duplication
Growth
Disease Progression
Ligands
Recurrence

Keywords

  • biomarker
  • colorectal cancer
  • Notch1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Arcaroli, J. J., Tai, W. M., Mcwilliams, R., Bagby, S., Blatchford, P. J., Varella-Garcia, M., ... Messersmith, W. A. (2016). A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. International Journal of Cancer, 138(1), 195-205. https://doi.org/10.1002/ijc.29676

A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. / Arcaroli, John J.; Tai, W. M.; Mcwilliams, Ryan; Bagby, Stacey; Blatchford, Patrick J.; Varella-Garcia, Marileila; Purkey, Alicia; Quackenbush, Kevin S.; Song, Eun Kee; Pitts, Todd M.; Gao, Dexiang; Lieu, Chris; Mcmanus, Martine; Tan, Aik-Choon; Zheng, Xianxian; Zhang, Qin; Ozeck, Mark; Olson, Peter; Jiang, Zhi Qin; Kopetz, Scott; Jimeno, Antonio; Keysar, Stephen; Eckhardt, Gail; Messersmith, Wells A.

In: International Journal of Cancer, Vol. 138, No. 1, 01.01.2016, p. 195-205.

Research output: Contribution to journalArticle

Arcaroli, JJ, Tai, WM, Mcwilliams, R, Bagby, S, Blatchford, PJ, Varella-Garcia, M, Purkey, A, Quackenbush, KS, Song, EK, Pitts, TM, Gao, D, Lieu, C, Mcmanus, M, Tan, A-C, Zheng, X, Zhang, Q, Ozeck, M, Olson, P, Jiang, ZQ, Kopetz, S, Jimeno, A, Keysar, S, Eckhardt, G & Messersmith, WA 2016, 'A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer', International Journal of Cancer, vol. 138, no. 1, pp. 195-205. https://doi.org/10.1002/ijc.29676
Arcaroli, John J. ; Tai, W. M. ; Mcwilliams, Ryan ; Bagby, Stacey ; Blatchford, Patrick J. ; Varella-Garcia, Marileila ; Purkey, Alicia ; Quackenbush, Kevin S. ; Song, Eun Kee ; Pitts, Todd M. ; Gao, Dexiang ; Lieu, Chris ; Mcmanus, Martine ; Tan, Aik-Choon ; Zheng, Xianxian ; Zhang, Qin ; Ozeck, Mark ; Olson, Peter ; Jiang, Zhi Qin ; Kopetz, Scott ; Jimeno, Antonio ; Keysar, Stephen ; Eckhardt, Gail ; Messersmith, Wells A. / A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. In: International Journal of Cancer. 2016 ; Vol. 138, No. 1. pp. 195-205.
@article{d458b1c7c5924c1e91d1834bac8c758a,
title = "A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer",
abstract = "Dysregulation of the Notch1 receptor has been shown to facilitate the development and progression of colorectal cancer (CRC) and has been identified as an independent predictor of disease progression and worse survival. Although mutations in the NOTCH1 receptor have not been described in CRC, we have previously discovered a NOTCH1 gene copy number gain in a portion of CRC tumor samples. Here, we demonstrated that a NOTCH1 gene copy number gain is significantly associated with worse survival and a high percentage of gene duplication in a cohort of patients with advanced CRC. In our CRC patient-derived tumor xenograft (PDTX) model, tumors harboring a NOTCH1 gain exhibited significant elevation of the Notch1 receptor, JAG1 ligand and cleaved Notch1 activity. In addition, a significant association was identified between a gain in NOTCH1 gene copy number and sensitivity to a Notch1-targeting antibody. These findings suggest that patients with metastatic CRC that harbor a gain in NOTCH1 gene copy number have worse survival and that targeting this patient population with a Notch1 antibody may yield improved outcomes. What's new? There is mounting evidence that the Notch1 receptor is important in modulating tumor growth and an independent predictor of survival in colorectal cancer (CRC). While mutations in the NOTCH1 receptor have not yet been described in CRC, this study shows that a gain in NOTCH1 gene copy number is associated with worse survival. Targeting cells with a specific Notch1 antibody resulted in potent antitumor growth in a CRC patient-derived tumor xenograft model. A NOTCH1 gene copy number gain may thus be a prognostic marker for disease recurrence as well as a predictive biomarker of sensitivity to a Notch1 targeted therapy.",
keywords = "biomarker, colorectal cancer, Notch1",
author = "Arcaroli, {John J.} and Tai, {W. M.} and Ryan Mcwilliams and Stacey Bagby and Blatchford, {Patrick J.} and Marileila Varella-Garcia and Alicia Purkey and Quackenbush, {Kevin S.} and Song, {Eun Kee} and Pitts, {Todd M.} and Dexiang Gao and Chris Lieu and Martine Mcmanus and Aik-Choon Tan and Xianxian Zheng and Qin Zhang and Mark Ozeck and Peter Olson and Jiang, {Zhi Qin} and Scott Kopetz and Antonio Jimeno and Stephen Keysar and Gail Eckhardt and Messersmith, {Wells A.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/ijc.29676",
language = "English",
volume = "138",
pages = "195--205",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer

AU - Arcaroli, John J.

AU - Tai, W. M.

AU - Mcwilliams, Ryan

AU - Bagby, Stacey

AU - Blatchford, Patrick J.

AU - Varella-Garcia, Marileila

AU - Purkey, Alicia

AU - Quackenbush, Kevin S.

AU - Song, Eun Kee

AU - Pitts, Todd M.

AU - Gao, Dexiang

AU - Lieu, Chris

AU - Mcmanus, Martine

AU - Tan, Aik-Choon

AU - Zheng, Xianxian

AU - Zhang, Qin

AU - Ozeck, Mark

AU - Olson, Peter

AU - Jiang, Zhi Qin

AU - Kopetz, Scott

AU - Jimeno, Antonio

AU - Keysar, Stephen

AU - Eckhardt, Gail

AU - Messersmith, Wells A.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Dysregulation of the Notch1 receptor has been shown to facilitate the development and progression of colorectal cancer (CRC) and has been identified as an independent predictor of disease progression and worse survival. Although mutations in the NOTCH1 receptor have not been described in CRC, we have previously discovered a NOTCH1 gene copy number gain in a portion of CRC tumor samples. Here, we demonstrated that a NOTCH1 gene copy number gain is significantly associated with worse survival and a high percentage of gene duplication in a cohort of patients with advanced CRC. In our CRC patient-derived tumor xenograft (PDTX) model, tumors harboring a NOTCH1 gain exhibited significant elevation of the Notch1 receptor, JAG1 ligand and cleaved Notch1 activity. In addition, a significant association was identified between a gain in NOTCH1 gene copy number and sensitivity to a Notch1-targeting antibody. These findings suggest that patients with metastatic CRC that harbor a gain in NOTCH1 gene copy number have worse survival and that targeting this patient population with a Notch1 antibody may yield improved outcomes. What's new? There is mounting evidence that the Notch1 receptor is important in modulating tumor growth and an independent predictor of survival in colorectal cancer (CRC). While mutations in the NOTCH1 receptor have not yet been described in CRC, this study shows that a gain in NOTCH1 gene copy number is associated with worse survival. Targeting cells with a specific Notch1 antibody resulted in potent antitumor growth in a CRC patient-derived tumor xenograft model. A NOTCH1 gene copy number gain may thus be a prognostic marker for disease recurrence as well as a predictive biomarker of sensitivity to a Notch1 targeted therapy.

AB - Dysregulation of the Notch1 receptor has been shown to facilitate the development and progression of colorectal cancer (CRC) and has been identified as an independent predictor of disease progression and worse survival. Although mutations in the NOTCH1 receptor have not been described in CRC, we have previously discovered a NOTCH1 gene copy number gain in a portion of CRC tumor samples. Here, we demonstrated that a NOTCH1 gene copy number gain is significantly associated with worse survival and a high percentage of gene duplication in a cohort of patients with advanced CRC. In our CRC patient-derived tumor xenograft (PDTX) model, tumors harboring a NOTCH1 gain exhibited significant elevation of the Notch1 receptor, JAG1 ligand and cleaved Notch1 activity. In addition, a significant association was identified between a gain in NOTCH1 gene copy number and sensitivity to a Notch1-targeting antibody. These findings suggest that patients with metastatic CRC that harbor a gain in NOTCH1 gene copy number have worse survival and that targeting this patient population with a Notch1 antibody may yield improved outcomes. What's new? There is mounting evidence that the Notch1 receptor is important in modulating tumor growth and an independent predictor of survival in colorectal cancer (CRC). While mutations in the NOTCH1 receptor have not yet been described in CRC, this study shows that a gain in NOTCH1 gene copy number is associated with worse survival. Targeting cells with a specific Notch1 antibody resulted in potent antitumor growth in a CRC patient-derived tumor xenograft model. A NOTCH1 gene copy number gain may thus be a prognostic marker for disease recurrence as well as a predictive biomarker of sensitivity to a Notch1 targeted therapy.

KW - biomarker

KW - colorectal cancer

KW - Notch1

UR - http://www.scopus.com/inward/record.url?scp=84944277142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944277142&partnerID=8YFLogxK

U2 - 10.1002/ijc.29676

DO - 10.1002/ijc.29676

M3 - Article

C2 - 26152787

AN - SCOPUS:84944277142

VL - 138

SP - 195

EP - 205

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -